Abstract：
BACKGROUND: Monoamine oxidase inhibitors (MAOIs) are considered third-line treatments for treatment resistant depression; however, they are underused in clinical practice.
OBJECTIVE: This study aimed to assess the efficacy, tolerability, and acceptability of MAOIs for the treatment of depression in comparison with other antidepressant treatments.
METHODS: A systematic review and network meta-analysis of randomised clinical trials was performed to compare the efficacy, tolerability and acceptability between MAOIs and other antidepressant treatments for the treatment of depressive episodes.
RESULTS: A total of 83 double-blinded, randomised controlled trials were included in the analysis, with 7765 participants assigned to an active treatment and 1844 assigned to placebo. Several MAOIs, including isocarboxazid, phenelzine, tranylcypromine and moclobemide, showed significantly higher efficacy compared with placebo. The tolerability and acceptability of MAOIs was comparable to other antidepressants.
CONCLUSIONS: A disproportionate number of studies investigating the most commonly used MAOIs, such as moclobemide and phenelzine, and a lack of specific studies focusing on treatment-resistant and atypical depression.
CONCLUSIONS: MAOIs are similar in efficacy to other antidepressants for the treatment of depression. However, more studies are needed comparing MAOI treatment in people with treatment-resistant, atypical and bipolar depression.
OBJECTIVE: This study aimed to assess the efficacy, tolerability, and acceptability of MAOIs for the treatment of depression in comparison with other antidepressant treatments.
METHODS: A systematic review and network meta-analysis of randomised clinical trials was performed to compare the efficacy, tolerability and acceptability between MAOIs and other antidepressant treatments for the treatment of depressive episodes.
RESULTS: A total of 83 double-blinded, randomised controlled trials were included in the analysis, with 7765 participants assigned to an active treatment and 1844 assigned to placebo. Several MAOIs, including isocarboxazid, phenelzine, tranylcypromine and moclobemide, showed significantly higher efficacy compared with placebo. The tolerability and acceptability of MAOIs was comparable to other antidepressants.
CONCLUSIONS: A disproportionate number of studies investigating the most commonly used MAOIs, such as moclobemide and phenelzine, and a lack of specific studies focusing on treatment-resistant and atypical depression.
CONCLUSIONS: MAOIs are similar in efficacy to other antidepressants for the treatment of depression. However, more studies are needed comparing MAOI treatment in people with treatment-resistant, atypical and bipolar depression.
摘要：
背景：单胺氧化酶抑制剂（MAOIs）被认为是治疗难治性抑郁症的三线疗法；然而，它们在临床实践中使用不足。
目的：本研究旨在评估疗效，耐受性,与其他抗抑郁治疗相比，MAOIs治疗抑郁症的可接受性。
方法：对随机临床试验进行系统评价和网络荟萃分析，以比较疗效。MAOIs和其他抗抑郁药治疗抑郁发作的耐受性和可接受性。
结果：共有83个双盲，随机对照试验纳入分析，7765名参与者被分配到积极治疗，1844名参与者被分配到安慰剂。几个MAOIs,包括异卡波肼,苯乙嗪,tranylcypromineandmoclobemide,与安慰剂相比，显示出显着更高的疗效。MAOIs的耐受性和可接受性与其他抗抑郁药相当。
结论：调查最常用的MAOIs的研究数量不成比例，如莫洛贝胺和苯乙嗪，缺乏针对抗治疗和非典型抑郁症的具体研究。
结论：MAOIs与其他抗抑郁药治疗抑郁症的疗效相似。然而,需要更多的研究比较MAOI治疗对治疗耐药的人，非典型和双相抑郁症。
目的：本研究旨在评估疗效，耐受性,与其他抗抑郁治疗相比，MAOIs治疗抑郁症的可接受性。
方法：对随机临床试验进行系统评价和网络荟萃分析，以比较疗效。MAOIs和其他抗抑郁药治疗抑郁发作的耐受性和可接受性。
结果：共有83个双盲，随机对照试验纳入分析，7765名参与者被分配到积极治疗，1844名参与者被分配到安慰剂。几个MAOIs,包括异卡波肼,苯乙嗪,tranylcypromineandmoclobemide,与安慰剂相比，显示出显着更高的疗效。MAOIs的耐受性和可接受性与其他抗抑郁药相当。
结论：调查最常用的MAOIs的研究数量不成比例，如莫洛贝胺和苯乙嗪，缺乏针对抗治疗和非典型抑郁症的具体研究。
结论：MAOIs与其他抗抑郁药治疗抑郁症的疗效相似。然而,需要更多的研究比较MAOI治疗对治疗耐药的人，非典型和双相抑郁症。
